You are here:Home-Inhibitors & Agonists-Apoptosis-Bcl-2

Request The Product List ofBcl-2 Bcl-2

Cat. No. Product Name CAS No. Information
PC-63502

S55746

1448584-12-0

S55746 (BCL201, Servier-1) is a novel potent, selective, orally bioavailable inhibitor of BCL-2 with Ki of 1.3 nM, 70- 400 fold selectivity over BCL-XL, on significant binding to MCL-1 and BFL-1; potently induces RS4;11 cell killing after 72 h of treatment with an IC50 of 71.6 nM, exhibits a much weaker activity in H146 (IC50 1.7 μM), a BCL-XL-dependent cell line; concentration-dependently disrupts the BCL-2/BAX complex in RS4;11 cells, selectively induces apoptosis through BCL-2 inhibition in a BAX/BAK-dependent manner; induces cell death in a panel of non-Hodgkin lymphoma cells; inhibits xenograft growth in RS4;11 and Toledo models.

Blood Cancer

Phase 1 Clinical

PC-62538

BCL6-IN-8

2204272-40-0

BCL6-IN-8 (BCL6-i) is a potent, irreversible and cell-active BCL6 inhibitor with inact/KI value of 1.9 × 104 M-1 s-1, targets Cys53 located at the protein-protein interaction interface; shows intracellular PPI inhibitory activity between BCL6 and its corepressors, thus resulting in BCL6-dependent DLBCL cell growth inhibition; BCL6-i is a cell-active chemical probe with the most potent BCL6 inhibitory activity reported to date.

PC-61404

AZD 5991

2143061-81-6

AZD 5991 (AZD5991) is a potent and selective macrocyclic inhibitor of Mcl-1 with sub-nanomolar affinity; promotes rapid apoptosis in Mcl-1-dependent cell lines (GI50=10 nM in multiple myeloma cell lines), disrupts Mcl-1/Bak complex; completely causes tumor regression in several mouse xenograft models after a single tolerated dose.

Blood Cancer

Phase 1 Clinical

PC-61318

(-) BI97D6

1256724-10-3

(-) BI97D6 (BI112D1) is a potent, pan-active inhibitor of Bcl-2 family proteins with IC50 of 76, 31, 25, and 122 nM for Bcl-xL, Bcl-2, Mcl-1, and Bfl-1, respectively; effectively inhibits cell growth in the PC-3 human prostate cancer and H23 human lung cancer cell lines with EC50 of 0.22 and 0.14  uM, respectively; effectively induces apoptosis in the BP3 human lymphoma cell line; displays in vivo efficacy in a prostate cancer xenograft model in mice; also overcomes ABT-737 resistance in AML, kills AML leukemia stem/progenitor cells while largely sparing normal hematopoietic stem/progenitor cells.

PC-60949

BI-3802

2166387-65-9

BI-3802 (BI3802) is a highly potent and efficacious BCL6 degrader that potently inhibits the interaction of the BTB/POZ domain of BCL6 with several co-repressors in vitro with IC50 of <3 nM; inhibits the BCL6/Co-repressor complex formation with IC50 of 43 nM in vitro, also is a potent and efficacious degrader of the BCL6 protein in many DLBCL cell lines (DC50=20 nM in SU-DHL-4 cells); BI-3802 is a valuable probe compound for testing hypotheses around BCL6 biology.

PC-60926

BCL6 inhibitor 79-6

301356-95-6

BCL6 inhibitor 79-6 (Compound 79-6) is the first-generation, specific BCL6 BTB domain inhibitor with IC50 of 200 uM, Kd of 129 uM; binds to a pocket in the lateral groove of the BCL6 BTB domain, specifically inhibits BCL6 but not other BTB-ZF proteins; disrupts BCL6/corepressor complexes and reactivates BCL6 target genes in vitro and in vivo, selectively kills BCL6-dependent DLBCL cells; suppresses human DLBCL xenografts in mice with favorable pharmacokinetics.

PC-70089

AMG-176

1883727-34-1

AMG-176 (AMG176) is a novel, potent and selective Mcl-1 inhibitor that binds with high affinity and selectivity to the BH3-binding groove of Mcl-1; disrupts the interaction between Mcl-1 and Bak, leading to downstream activation of the intrinsic apoptosis pathway in a cell based split-luciferase complementation assay; shows robust anti-tumor activity in Mcl-1 dependent cancer models; orally bioavailable.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com